Compare GH & ZTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GH | ZTO |
|---|---|---|
| Founded | 2011 | 2002 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Advertising |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.8B | 17.3B |
| IPO Year | 2018 | 2016 |
| Metric | GH | ZTO |
|---|---|---|
| Price | $101.85 | $24.09 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 21 | 4 |
| Target Price | ★ $102.81 | $21.90 |
| AVG Volume (30 Days) | 2.1M | ★ 2.2M |
| Earning Date | 02-19-2026 | 03-17-2026 |
| Dividend Yield | N/A | ★ 2.54% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.16 |
| Revenue | $902,569,000.00 | ★ $6,673,175,085.00 |
| Revenue This Year | $35.23 | $12.15 |
| Revenue Next Year | $27.38 | $11.36 |
| P/E Ratio | ★ N/A | $20.37 |
| Revenue Growth | ★ 30.38 | 13.17 |
| 52 Week Low | $34.88 | $16.34 |
| 52 Week High | $120.74 | $23.81 |
| Indicator | GH | ZTO |
|---|---|---|
| Relative Strength Index (RSI) | 38.60 | 73.13 |
| Support Level | $97.88 | $21.69 |
| Resistance Level | $118.00 | $23.81 |
| Average True Range (ATR) | 5.67 | 0.41 |
| MACD | -1.94 | 0.13 |
| Stochastic Oscillator | 11.61 | 99.79 |
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced-stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant Omni, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
ZTO Express is China's largest express delivery company by parcel volume, with a volume share of 19.4% in 2024. It operates a network partner model where it provides line-haul transportation and sorting services, while its local network partners provide first-mile pickup and last-mile delivery services under the ZTO brand name. Headquartered in Shanghai, the company was founded in 2002 by Meisong Lai, who remains chair, CEO, and its major shareholder with 78% voting rights as of March 31, 2025. ZTO's strategic shareholder is leading China e-commerce company Alibaba Group with around an 8.9% interest.